Nektar Therapeutics (NKTR) Getting Somewhat Favorable Media Coverage, Study Shows

News stories about Nektar Therapeutics (NASDAQ:NKTR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nektar Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.638084621397 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Nektar Therapeutics (NKTR) traded up $2.12 during trading on Friday, hitting $72.00. 1,904,805 shares of the stock were exchanged, compared to its average volume of 2,717,111. Nektar Therapeutics has a twelve month low of $11.41 and a twelve month high of $73.95. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91. The firm has a market capitalization of $11,340.00, a price-to-earnings ratio of -101.41 and a beta of 1.81.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.16. Nektar Therapeutics had a net margin of 39.80% and a return on equity of 557.76%. The business had revenue of $152.90 million for the quarter, compared to analyst estimates of $126.50 million. During the same period in the previous year, the business posted ($0.32) earnings per share. The business’s revenue was up 321.2% compared to the same quarter last year. equities analysts forecast that Nektar Therapeutics will post -0.75 EPS for the current fiscal year.

A number of research firms have commented on NKTR. Canaccord Genuity Group lifted their price objective on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, November 15th. Cowen began coverage on shares of Nektar Therapeutics in a research note on Tuesday, November 7th. They issued an “outperform” rating on the stock. Canaccord Genuity began coverage on shares of Nektar Therapeutics in a research note on Thursday, November 9th. They issued a “buy” rating and a $35.00 price objective on the stock. Roth Capital set a $45.00 price objective on shares of Nektar Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. Finally, Zacks Investment Research lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $38.08.

In related news, SVP Stephen K. Doberstein sold 396,323 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $29.00, for a total transaction of $11,493,367.00. Following the sale, the senior vice president now owns 52,016 shares of the company’s stock, valued at $1,508,464. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Howard W. Robin sold 83,334 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $23.57, for a total transaction of $1,964,182.38. Following the sale, the chief executive officer now directly owns 235,838 shares in the company, valued at approximately $5,558,701.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 614,017 shares of company stock worth $20,587,527. Company insiders own 5.44% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/12/nektar-therapeutics-nktr-getting-somewhat-favorable-media-coverage-study-shows.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit